Update from PTC Therapeutics
In a community letter on May 29, 2026, PTC Therapeutics shared that they will be initiating a new clinical trial for vatiquinone for the treatment of individuals living with Friedreich’s ataxia from 7 to 21 years of age. PTC expects this study to start enrolling in the third quarter of this year. The study design was based on discussions with the FDA and all participants will receive vatiquinone following enrollment—there will not be a placebo group.
Learn more about PTC Therapeutics’ vatiquinone program on our pipeline page.